Why Analytica Limited shares were slammed 29% today

Analytica Limited (ASX:ALT) shareholders are stomaching a huge loss this morning after the company emerged from a trading halt.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of Analytica Limited (ASX: ALT) have been smashed by the market today after the company emerged from a trading halt, announcing a material capital raising. The stock plunged 29.4% to a low of 1.2 cents, compared to a 1.1% decline for the benchmark ALL ORDINARIES (Index: ^AXAO) (ASX: XAO).

Analytica is a micro-cap business whose lead product is the PeriCoach System – an e-health treatment system designed to strengthen the pelvic floor muscle for women who suffer Stress Urinary Incontinence. It then gives feedback to the user via a smart phone.

Although the potential for such a system is enormous, there are also a number of challenges including the difficulty of marketing (it's unlikely to gain traction via word-of-mouth) while smart-phone usage is also far less prevalent amongst older generations.

Capital Raising

On Monday, Analytica was forced to respond to a speeding ticket issued by the ASX relating to a jump in share price on the back of unusually high volumes. The company requested a trading halt and stated that it was in advanced preparations for a capital raising.

Today, the $16 million company announced that it was raising up to $3.7 million by way of a renounceable pro-rata offer (Rights Issue), offering one new share for every two shares held at the record date. The shares will be allocated to shareholders who choose to participate at an issue price of 0.8 cents per share, which represents a 33% discount to today's price.

The funds will also be used by the company to fund marketing costs in connection with the launch of the PeriCoach System, predominantly in the USA but also in Europe, as well as for general working capital.

Should you buy?

Analytica is by no means a risk-free bet and should only be considered by the more risk-tolerant investment crowd until the company can prove its worth. Until then, investors wanting to gain exposure to the medical device industry could consider looking at alternatives such as ResMed Inc. (CHESS) (ASX: RMD) or Somnomed Limited (ASX:SOM), both of which manufacture devices for the treatment of obstructive sleep apnea.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. You can follow Ryan on Twitter @ASXvalueinvest.

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »